SANTA MONICA, Calif., Jan. 3, 2019 /PRNewswire/ -- DeciBio Consulting, LLC, a precision medicine-focused strategy consulting and market intelligence firm, has released their 2019 Liquid Biopsy Market Report and Stakeholder Toolkit. DeciBio's analysis estimates the clinical oncology liquid biopsy manufacturers' market at ~$200 million in 2018, growing at ~40% annually to reach $1 billion by 2023.
The liquid biopsy market has seen dramatic investment in the past few years, with liquid biopsy companies raising over $4 billion since 2015. DeciBio expects growth in the liquid biopsy market, led by such companies as GRAIL and Guardant Health, to be driven by technological improvements, demonstration of clinical utility, and expanded inclusion in clinical guidelines. This growth could be moderated by such factors as limited or delayed reimbursement by commercial payers and unforeseen biological limitations that require additional R&D investment, such as variability in circulating analyte levels.
Even at a market size of one billion dollars in 5 years, DeciBio founding partner Stephane Budel, Ph.D., believes that will just be scratching the surface. "The reality is the liquid biopsy market can be orders of magnitude larger than the tissue testing market," says Budel, "because it can be used throughout the patient journey."
The report also covers the competitive landscape and market analysis, and provides guidelines for entrepreneurs, investors, payers and biopharma partners interested in entering the liquid biopsy space. It is now available for purchase on DeciBio's website at https://www.decibio.com/intelligence/liquid-biopsy-fad-or-future-market-report/.
DeciBio is a strategy consulting and market intelligence firm focused on precision medicine. DeciBio offers advisory services for growth planning, market and opportunity assessment, product and portfolio strategy and corporate due diligence. The company also offers market intelligence products, including several life science market reports and data visualization and analysis platforms for immuno-oncology, liquid biopsy, cancer biomarkers and more.
DeciBio Consulting, LLC
SOURCE DeciBio Consulting, LLC